title: AIB1Genomic Amplification Predicts Poor Clinical Outcomes in Female Glioma Patients.
abstract: Amplified in breast cancer 1(AIB1) gene, a coactivator for steroid receptor, is frequently amplified in diverse cancers and is considered as an oncogene in tumorigenesis. However, the prognostic significance ofAIB1amplification in gliomas remains totally unclear. In this study, 115 gliomas and 16 benign meningiomas as control subjects were enrolled, and the copy number ofAIB1was analyzed in these samples. In addition, we explored potential correlation ofAIB1amplification with clinicopathological characteristics and clinical outcomes of glioma patients. Our data showed that glioma samples exhibited a significantly higherAIB1copy number than control subjects as determined by quantitative polymerase chain reaction (qPCR) approach. Moreover, univariate analysis showed thatAIB1amplification (≥3.5 copies) was strongly correlated with cancer-related death (P =0.03). Interestingly, our data revealed a significant association ofAIB1amplification with WHO grade (P =0.03), tumor recurrence (P =0.03) and survival status (P =0.03) in female patients but not in male patients. Multivariate analysis further demonstrated thatAIB1amplification was independent factor for cancer-related death in female patients. Importantly,AIB1amplification was closely relevant to worse survival in female patients (P =0.001), but not in male patients (P =1.00). In addition, the patients withAIB1amplification were resistant to radiotherapy. Altogether, our data demonstrate thatAIB1amplification is a common genetic event in glioma tumorigenesis, and suggest thatAIB1amplification is not only a prognostic factor for poor clinical outcomes in glioma patients, but also a predictor of radiotherapy resistance in gliomas.
authors.affiliation: Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China.
authors.forename: Lihong
authors.initials: L
authors.lastname: Chen
authors.affiliation: Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, The People's Republic of China.
authors.forename: Changwei
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of Biochemistry, McMaster University, Hamilton, Ontario L8S 4L8, Canada.
authors.forename: Xinyuan
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China.
authors.forename: Ke
authors.initials: K
authors.lastname: Gao
authors.affiliation: Department of Radio Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China.
authors.forename: Rui
authors.initials: R
authors.lastname: Liu
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China.
authors.forename: Bingyin
authors.initials: B
authors.lastname: Shi
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China.
authors.forename: Peng
authors.initials: P
authors.lastname: Hou
keywords: AIB1 amplification; Glioma; clinical outcomes; radiotherapy resistance